Cystic Fibrosis and the Clinical Biofilm Revolution A Survey of the Danish CF Center's Contribution

Overview

Journal Biofilm

Date 2025 Jan 15

PMID 39811797

Authors

Niels Hoiby

Affiliations

Soon will be listed here.

Abstract

Biofilm infections are chronic infections which are difficult to diagnose. Biofilm infections are tolerant to antibiotics and the defense mechanisms of the host. Patients with the genetic disease cystic fibrosis (CF) produce viscid mucus in the respiratory tract and therefore suffer from chronic biofilm infections in their lungs and paranasal sinuses. The most important microorganism is the mucoid phenotype of which causes chronic biofilm infections in the lungs of CF patients and untreated patients succumb as children if they contact this biofilm infection. Since CF patients are treated in CF Centers all over the world, it is possible to do longitudinal studies on epidemiology, pathophysiology, diagnosis, prevention and treatment of biofilm infection which is not possible if such patients are not followed in specialized centers. This survey describes the research through several decades in the Danish CF Center in Copenhagen which have changed the epidemiology, treatment, prophylaxis and prognosis of CF patients worldwide. Based on these results ESCMID Guidelines for diagnosis and treatment of biofilm infections were published which have influenced biofilm research and treatment in other areas.

References

Massie J, Gillam L . Uncertain diagnosis after newborn screening for cystic fibrosis: An ethics-based approach to a clinical dilemma. Pediatr Pulmonol. 2013; 49(1):1-7. DOI: 10.1002/ppul.22933. View

Dwyer D, Collins J, Walker G . Unraveling the physiological complexities of antibiotic lethality. Annu Rev Pharmacol Toxicol. 2014; 55:313-32. DOI: 10.1146/annurev-pharmtox-010814-124712. View

Ratjen F . The future of cystic fibrosis: A global perspective. Pediatr Pulmonol. 2024; . DOI: 10.1002/ppul.27337. View

Valerius N, Koch C, Hoiby N . Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991; 338(8769):725-6. DOI: 10.1016/0140-6736(91)91446-2. View

Bisgaard H, Pedersen S, Nielsen K, Skov M, Laursen E, Kronborg G . Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. Am J Respir Crit Care Med. 1997; 156(4 Pt 1):1190-6. DOI: 10.1164/ajrccm.156.4.9612044. View

Fernandez-Barat L, Ciofu O, Kragh K, Pressler T, Johansen U, Motos A . Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. J Cyst Fibros. 2016; 16(2):222-229. DOI: 10.1016/j.jcf.2016.08.005. View

Mauch R, Rossi C, Aiello T, Ribeiro J, Ribeiro A, Hoiby N . Secretory IgA response against Pseudomonas aeruginosa in the upper airways and the link with chronic lung infection in cystic fibrosis. Pathog Dis. 2017; 75(6). DOI: 10.1093/femspd/ftx069. View

Kolpen M, Hansen C, Bjarnsholt T, Moser C, Christensen L, van Gennip M . Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax. 2009; 65(1):57-62. DOI: 10.1136/thx.2009.114512. View

Littlewood J, Miller M, Ghoneim A, RAMSDEN C . Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985; 1(8433):865. DOI: 10.1016/s0140-6736(85)92222-6. View

Hoiby N, Pedersen S . Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand. 1989; 78(3):395-404. DOI: 10.1111/j.1651-2227.1989.tb11099.x. View

Tan W, Verma V, Jeong K, Kim S, Jung C, Lee S . Molecular characterization of vulnibactin biosynthesis in Vibrio vulnificus indicates the existence of an alternative siderophore. Front Microbiol. 2014; 5:1. PMC: 3900857. DOI: 10.3389/fmicb.2014.00001. View

10.

Saiman L, Macdonald N, Burns J, Hoiby N, Speert D, Weber D . Infection control in cystic fibrosis: practical recommendations for the hospital, clinic, and social settings. Am J Infect Control. 2000; 28(5):381-5. DOI: 10.1067/mic.2000.106337. View

11.

Ahmed M, Porse A, Abdelsamad A, Sommer M, Hoiby N, Ciofu O . Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms. Antimicrob Agents Chemother. 2019; 63(10). PMC: 6761533. DOI: 10.1128/AAC.00766-19. View

12.

Frederiksen B, Koch C, Hoiby N . Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997; 23(5):330-5. DOI: 10.1002/(sici)1099-0496(199705)23:5<330::aid-ppul4>3.0.co;2-o. View

13.

Line L, Alhede M, Kolpen M, Kuhl M, Ciofu O, Bjarnsholt T . Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum. Front Microbiol. 2014; 5:554. PMC: 4208399. DOI: 10.3389/fmicb.2014.00554. View

14.

Jorgensen K, Wassermann T, Jensen P, Hengzuang W, Molin S, Hoiby N . Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013; 57(9):4215-21. PMC: 3754285. DOI: 10.1128/AAC.00493-13. View

15.

Pressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, Hoiby N . Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros. 2011; 10 Suppl 2:S75-8. DOI: 10.1016/S1569-1993(11)60011-8. View

16.

Schiotz P, Hoiby N, Permin H, Wiik A . IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis. Acta Pathol Microbiol Scand C. 1979; 87C(3):229-33. View

17.

Hoiby N, FLENSBORG E, Beck B, Friis B, Jacobsen S, Jacobsen L . Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977; 58(2):65-79. View

18.

Alanin M, Pressler T, Aanaes K, Ekstrom C, Skov M, Krogh Johansen H . Can secretory immunoglobulin A in saliva predict a change in lung infection status in patients with cystic fibrosis? A prospective pilot study. Health Sci Rep. 2019; 1(8):e52. PMC: 6266372. DOI: 10.1002/hsr2.52. View